Monthly research recap
DMT research: March 2026
What March 2026's 10 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 6 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, 5-MeO-DMT, then ranked by relevance.
Research on DMT in March 2026 was limited to a few small-scale studies and theoretical proposals. One double-blind, placebo-controlled trial in 20 healthy participants found that intravenous bolus DMT produces very strong, short-lived subjective effects with a ceiling at 15 mg and no acute tolerance, but tolerability was better with open-label dosing. Other studies were either in-silico toxicity predictions, computational sensor designs, or theoretical protocols for testing quantum spin effects, with no direct clinical efficacy data from this period.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Dose-dependent pharmacokinetics and acute effects of intravenous bolus N,N-dimethyltryptamine: double-blind, randomized versus open-label dose-escalation administration study in healthy participants 2026 | RCT (double-blind, placebo-controlled, crossover) + open-label dose-escalation | 20 | Supports | Intravenous bolus DMT produced very strong subjective effects with rapid onset and peak within 2 minutes, declining within 12-30 minutes, with a ceiling effect at 15 mg and no acute tolerance. |
| In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin. 2026 | in-silico computational study | Unclear | In-silico toxicity predictions classified DMT as high toxicological concern with moderate-to-high acute oral toxicity and potential cardiotoxicity via hERG inhibition. | |
| Isotopic DMT as a Probe of Spinorial Consciousness 2026 | theoretical protocol | Unclear | Proposed a protocol using isotopic DMT to test the radical pair mechanism in consciousness, but no experimental data were reported. | |
| Computational evaluation of aluminum and zinc doped C20 fullerenes as advanced sensors for the detection of the narcotic dimethyltryptamine 2026 | computational study | Unclear | Computational evaluation suggested zinc-doped C20 fullerenes as promising sensors for DMT detection, but no empirical validation was provided. | |
| Nuclear Spin Modulation of Psychedelic Consciousness States: A Factorial fMRI Protocol Combining N,N-DMT with Krypton and Xenon Isotopes 2026 | theoretical protocol | Unclear | Proposed a factorial fMRI protocol combining DMT with noble gas isotopes to test nuclear spin modulation of consciousness, but no data were collected. | |
| DMT microstates 2026 | dataset description | Unclear | Described a dataset on DMT and harmine formulation altering metastable EEG topography sequences, but no results were reported in the abstract. |
Points of agreement
- DMT produces rapid-onset, short-duration subjective effects when administered intravenously.
- Computational models predict potential toxicity and cardiotoxicity risks for DMT.
Conflicts
- No direct conflicts among the studies, as they address different aspects (pharmacokinetics, toxicity, theoretical models) without overlapping empirical findings.
Gaps
- No clinical efficacy or safety data from March 2026 for DMT in patient populations.
- Lack of studies on long-term effects, repeated dosing, or therapeutic outcomes.
- No empirical testing of the proposed quantum spin or isotopic DMT protocols.
- No studies on DMT's effects in diverse populations or with standardized dosing regimens beyond the single trial.